Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Hakeam A HakeamAmal ArabAyman AzzamZyad AlyahyaAbdelmoneim M EldaliTarek Amin

Published in: Cancer chemotherapy and pharmacology (2018)

Melphalan and CIS + MMC regimens were associated with comparable incidences of leukopenia and thrombocytopenia. Severe leukopenia and severe thrombocytopenia were rare following CRS/HIPEC using both chemotherapy regimens.

Keyphrases

high dose
patients undergoing
locally advanced
early onset
minimally invasive
risk factors
drug induced
radiation therapy
coronary artery disease
atrial fibrillation